𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas

✍ Scribed by John H. Edmonson; Harry J. Long; Ronald L. Richardson; Edward T. Creagan; Stephanie J. Green

Publisher
Springer
Year
1985
Tongue
English
Weight
216 KB
Volume
15
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Combined cisplatin, doxorubicin, and mit
Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma : A Phase II FONICAP trial
✍ Maria Cristina Pennucci; Andrea Ardizzoni; Paolo Pronzato; Marina Fioretti; Clau πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 182 KB πŸ‘ 2 views

and cisplatin (P) yielded an objective response rate of 25% and a subjective response rate of 50% in patients with mesothelioma. In human mesothelioma cell

Cyclophosphamide, Doxorubicin, and Cispl
Cyclophosphamide, Doxorubicin, and Cisplatin Combined in the Treatment of Advanced Sarcomas
✍ Edmonson, John H. ;Hahn, Richard G. ;Schutt, Allan J. ;Bisel, Harry F. ;Ingle, J πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 English βš– 202 KB

Twenty-five patients with evaluable histologically confirmed inoperable metastatic sarcomas were treated once every four weeks with cyclophosphamide, doxorubicin, and cisplatin in doses of 400, 40, and 60 mg/m2, respectively. Cyclophosphamide and doxorubicin were given by rapid intravenous injection

Phase II study of a modified combination
Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer
✍ IΓ§li, Fikri; Karaoguz, Handan; Akbulut, Hakan; DinΓ§ol, Dilek; Demirkazik, Ahmet; πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 52 KB πŸ‘ 2 views

## Background: Based on the promising results of eap (etoposide, doxorubicin, and cisplatin) combination, a phase ii study of modified eap combination was performed in patients with advanced gastric cancer to evaluate the response, toxicity, and survival. ## Method: Fifty-two consecutive patients